William Blair analyst Raju Prasad started bluebird bio with an Outperform rating and $242 fair value estimate. Management is executing well on becoming a company with two-plus products on the market, two-plus programs nearing commercialization, and four-plus additional programs by 2022, Prasad tells investors in a research note titled "Suit Up! 2018 Could Be Another Blue-Ribbon Year." The analyst sees this year's catalysts centering around three medical conferences which he thinks have the potential to enhance bluebird bio's status as a leading innovator in cell and gene therapies.